Literature DB >> 15337026

Apoptosis-related mitochondrial dysfunction in the early postoperative neonatal lamb heart.

Christopher A Caldarone1, Elesa W Barner, Lixing Wang, Mohsen Karimi, Christopher E Mascio, James M Hammel, Jeffrey L Segar, Changqing Du, Thomas D Scholz.   

Abstract

BACKGROUND: In the early postoperative period, the neonatal myocardium undergoes sparse apoptotic cell loss ( approximately 1% of myocytes). Because apoptosis is preceded by events associated with mitochondrial dysfunction, the fraction of myocytes with preapoptotic mitochondrial changes has important clinical implications (eg, postoperative myocardial dysfunction). My colleagues and I therefore hypothesized that postoperative apoptotic myocytes represent a tip of the iceberg, with more myocytes upstream with apoptosis-related mitochondrial dysfunction (ARMD).
METHODS: Neonatal lambs underwent cardiopulmonary bypass, 60 minutes of cardioplegic arrest, and 6 hours of recovery (cardiopulmonary bypass with cardioplegic arrest [CPB+CP]; n = 5) and were compared with nonbypass controls (non-CPB; n = 5). Myocardium (left ventricle [LV] and right ventricle [RV]) was examined by using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining, electron microscopy, immunohistochemistry, Western blot, and isolated mitochondrial oxygen consumption measurement.
RESULTS: TUNEL-positive nuclei and electron microscopy-confirmed mitochondrial structural changes were more common in CPB+CP than non-CPB myocardium and were more common in the LV than RV (p = 0.0016). Bax (a proapoptotic mediator) translocated from the cytosol to the mitochondria (LV > RV; p < 0.05). Immunohistochemistry demonstrated diffuse mitochondrial loss of cytochrome c that was consistent with outer mitochondrial membrane permeabilization (LV > RV > non-CPB). Permeabilization was further demonstrated by augmentation of oxygen consumption in isolated mitochondria after administration of exogenous cytochrome c. The mitochondrial oxygen consumption boost was 57% for CPB+CP:LV; 23% for CPB+CP:RV; and 18% and 17% for non-CPB:LV and non-CPB:RV, respectively (p < 0.01, CPB+CP:LV vs other groups).
CONCLUSIONS: ARMD is much greater than the prevalence of TUNEL-positive myocytes in postoperative neonatal myocardium. Greater LV vulnerability may represent a relationship between increased afterload and ARMD. These changes are consistent with the early postoperative myocardial dysfunction commonly reported after neonatal cardiac operations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337026     DOI: 10.1016/j.athoracsur.2004.04.031

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Therapeutic effects of Shenfu Injection on post-cardiac arrest syndrome.

Authors:  Zhi-jun Guo; Chun-sheng Li
Journal:  Chin J Integr Med       Date:  2013-08-24       Impact factor: 1.978

Review 2.  Endocrine and other physiologic modulators of perinatal cardiomyocyte endowment.

Authors:  S S Jonker; S Louey
Journal:  J Endocrinol       Date:  2015-10-02       Impact factor: 4.286

3.  Ginkgo biloba extract reducing myocardium cells apoptosis by regulating apoptotic related proteins expression in myocardium tissues.

Authors:  Zeng Yong Qiao; Jian Hua Huang; Jiang Wei Ma; Ya Wei Xu; Jun Xie; Hua Jin Liu; San Jun Xiong; Guang Hao Ge
Journal:  Mol Biol Rep       Date:  2013-12-08       Impact factor: 2.316

4.  Cardiopulmonary bypass reduces myocardial oxidative stress, inflammation and increases c-kit+CD45- cell population in newborns.

Authors:  Johannes Petersen; Andrey Kazakov; Michael Böhm; Hans-Joachim Schäfers; Ulrich Laufs; Hashim Abdul-Khaliq
Journal:  J Transl Med       Date:  2018-04-27       Impact factor: 5.531

5.  Myocardial histology and outcome after cardiopulmonary bypass of neonatal piglets.

Authors:  Theodor Tirilomis; Marc Bensch; Regina Waldmann-Beushausen; Friedrich A Schoendube
Journal:  J Cardiothorac Surg       Date:  2015-11-20       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.